Hims & Hers Health (HIMS) said Monday in a letter to shareholders it plans to launch diabetes drug Liraglutide on its platform in 2025.
The company said it has already confirmed a core supplier for the drug, which is a generic version of Novo Nordisk's (NVO) type-2 diabetes treatment Victoza, and that it expects to complete test and batch validation over the next few months.
Price: 22.47, Change: +1.71, Percent Change: +8.24
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.